Shen et al. found that MCM3AP-AS1 was overexpressed in non-small-cell lung cancer (NSCLC), and MCM3AP-AS1 may be a promising therapeutic target for NSCLC patients [39]. This evidence concerns the gene MCM3AP and non-small cell lung carcinoma.